SCHEMBL4307749

SCHEMBL4307749

O=Cc1cccc(N(c2ccccc2)c2ccccc2)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.50
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
TLR2 O60603 1/20 0.43
TLR1 Q15399 1/20 0.43
TLR6 Q9Y2C9 1/20 0.43
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
APP P05067 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL50149 0.83 KMT2A (0.50) ERN1TRIM24TRIM33LMNAKMT2A
SCHEMBL7605635 0.80 KMT2A (0.43) ERN1TRIM24TRIM33LMNAKMT2A
SCHEMBL29613044 0.80 KMT2A (0.43) ERN1TRIM24TRIM33LMNAKMT2A
SCHEMBL31298129 0.79 KMT2A (0.50) ERN1TRIM24TRIM33LMNAKMT2A
SCHEMBL14337062 0.77 SIRT2 (0.50) LMNAKMT2AMEN1THRBTDP1
SCHEMBL1982670 0.76 ERN1 (0.52) ERN1TRIM24TRIM33TLR2TLR1
Salicyladehyde SCHEMBL29002930 0.76 TRIM24 (0.72) ERN1TRIM24TRIM33LMNAKMT2A
SCHEMBL2844043 0.76 ERN1 (0.55) ERN1TRIM24TRIM33TLR2TLR1
SCHEMBL5881115 0.75 ALDH1A1 (0.46) ERN1LMNATHRBBLMTDP1
SCHEMBL279011 0.75 KMT2A (0.44) TRIM24TRIM33LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815811-B2 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. (IN) 2017-11-14 US disclosed
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY CURADEV PHARMA PRIVATE LTD. (IN) 2016-02-18 US disclosed
US-7569694-B2 Coumarin compound, material for light emitting device and organic electroluminescent device CHISSO CORPORATION (JP) 2009-08-04 US disclosed
US-20070176544-A1 Coumarin compound, material for light emitting device and organic electroluminescent device JNC CORPORATION (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070176544-A1 Coumarin compound, material for light emitting device and organic electroluminescent device TRPA1, CYP3A4, UGT1A10 ERN1 1549/4885TRIM24 1274/4885TRIM33 3908/4885
US-20160046596-A1 INHIBITORS OF THE KYNURENINE PATHWAY IDO1, KYNU, IDO2 ERN1 2785/4885TRIM24 2830/4885TRIM33 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.